Benralizumab (Fasenra®)

Assessment Status Rapid Review complete
Drug Benralizumab
Brand Fasenra®
Indication As add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
Assessment Process
Rapid review commissioned 15/01/2018
Rapid review completed 14/02/2018
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the Submitted Price

The HSE has approved reimbursement following confidential price negotiations; April 2019